Cited 7 times in
High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 송미경 | - |
dc.contributor.author | 신동엽 | - |
dc.contributor.author | 이은직 | - |
dc.contributor.author | 황세나 | - |
dc.date.accessioned | 2016-02-04T11:09:28Z | - |
dc.date.available | 2016-02-04T11:09:28Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1355-008X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/139794 | - |
dc.description.abstract | There are scarce reports regarding a functional prognostic value of thyroid-stimulating autoantibody (TSAb) levels using a thyroid-stimulating hormone receptor chimera (Mc4) in Graves' disease (GD) in iodine sufficient area. The aim of this study was to investigate whether Mc4-TSAb can predict GD remission/relapse after antithyroid drug (ATD) treatment and to compare Mc4-TSAb with a binding assay using M22 monoclonal antibody (M22-TRAb) in GD patients. We retrospectively reviewed the results of M22-TRAb and Mc4-TSAb in GD patients treated with ATD for 12 months. GD patients who underwent ATD treatment for at least 12 months were included. We compared the predictive values of M22-TRAb and Mc4-TSAb for GD remission and relapse. Of the 92 patients, 60 (65.2%) achieved remission and 32 (34.8%) relapsed within 12 months. In receiver operating characteristic analysis, there were no significant differences in the area under the curves (AUCs) between Mc4-TSAb [AUC=0.79 (95% CI 0.69-0.89)] and M22-TRAb [AUC=0.69 (95% CI 0.58-0.81)]. The optimal predictive cut-off values of M22-TRAb and Mc4-TSAb were 2.23 IU/L and 230%, respectively. At a high Mc4-TSAb cut-off, the better specificity of 85.0% and positive predictive value (PPV) of 69.0% were shown compared with those at the best cut-off for M22-TRAb. In conclusion, a high cut-off for an Mc4 assay may improve the predictive value of relapse with superior specificity and PPV compared with M22-TRAb in treated GD. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 89~95 | - |
dc.relation.isPartOf | ENDOCRINE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Antithyroid Agents/therapeutic use | - |
dc.subject.MESH | Biological Assay | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Graves Disease/diagnosis* | - |
dc.subject.MESH | Graves Disease/drug therapy | - |
dc.subject.MESH | Graves Disease/genetics* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulins, Thyroid-Stimulating/analysis | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Mutant Chimeric Proteins/genetics* | - |
dc.subject.MESH | Predictive Value of Tests | - |
dc.subject.MESH | Prognosis | - |
dc.subject.MESH | Receptors, Thyrotropin/genetics* | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | High cut-off value of a chimeric TSH receptor (Mc4)-based bioassay may improve prediction of relapse in Graves' disease for 12 months | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Yonsei Biomedical Research Center (연세의생명연구원) | - |
dc.contributor.googleauthor | Sena Hwang | - |
dc.contributor.googleauthor | Dong Yeob Shin | - |
dc.contributor.googleauthor | Mi Kyung Song | - |
dc.contributor.googleauthor | Eun Jig Lee | - |
dc.identifier.doi | 10.1007/s12020-014-0325-8 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02020 | - |
dc.contributor.localId | A02093 | - |
dc.contributor.localId | A03050 | - |
dc.contributor.localId | A04468 | - |
dc.relation.journalcode | J00768 | - |
dc.identifier.eissn | 1559-0100 | - |
dc.identifier.pmid | 24968734 | - |
dc.identifier.url | http://link.springer.com/article/10.1007%2Fs12020-014-0325-8 | - |
dc.subject.keyword | TSH-receptor antibody | - |
dc.subject.keyword | Mc4 bioassay | - |
dc.subject.keyword | M22 monoclonal antibody | - |
dc.subject.keyword | Graves’ disease | - |
dc.subject.keyword | Predictive value | - |
dc.contributor.alternativeName | Song, Mi Kyung | - |
dc.contributor.alternativeName | Shin, Dong Yeob | - |
dc.contributor.alternativeName | Lee, Eun Jig | - |
dc.contributor.alternativeName | Hwang, Se Na | - |
dc.contributor.affiliatedAuthor | Song, Mi Kyung | - |
dc.contributor.affiliatedAuthor | Shin, Dong Yeob | - |
dc.contributor.affiliatedAuthor | Lee, Eun Jig | - |
dc.contributor.affiliatedAuthor | Hwang, Se Na | - |
dc.rights.accessRights | not free | - |
dc.citation.volume | 48 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 89 | - |
dc.citation.endPage | 95 | - |
dc.identifier.bibliographicCitation | ENDOCRINE, Vol.48(1) : 89-95, 2015 | - |
dc.identifier.rimsid | 53825 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.